Nanjing Synnocare Pharmaceutical Technology Co., Ltd. focuses on unmet clinical needs and targets that are difficult to develop drugs. In malignancies, autoimmune diseases, central nervous system disorders and other fields, we integrate AI and multi-omics technology into the whole process of new drug development from target discovery to drug molecule design and clinical trial design. We are committed to developing original new small molecule drugs with global intellectual property rights.
Staff with Master or Doctoral Degrees
Focuses on unmet clinical needs and targets that are difficult to develop drugs